anti-cancer biosimilar
Scope
Date
~
-
Bio & Pharma
Investors dump Korean biotech HLB stocks on FDA rejection
HLB Co. and its affiliate stocks tumbled on Friday on news that the South Korean biotech group’s highly anticipated new cancer treatment Rivoc...
May 17, 2024 (Gmt+09:00)
-
Bio & Pharma
S.Korean anti-obesity drugmakers eye niche demand
The global weight management market has entered a new chapter following the arrival of blockbuster weight-loss medication Wegovy, and South Korean l...
May 07, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima, Herzuma to Peru
South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...
May 02, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis gets OK to sell Stelara biosimilar in Europe
South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...
Apr 23, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung begins new drug development for rare diseases
Samsung Bioepis Co., a biosimilar development unit of South Korea’s top conglomerate Samsung Group, has begun its new drug development busines...
Mar 24, 2024 (Gmt+09:00)
-
Artificial intelligence
LG, Jackson Lab to jointly develop AI models for Alzheimer’s, cancers
LG AI Research, the artificial intelligence research arm of South Korea’s LG Group, and the Jackson Laboratory (JAX), a US non-profit biomedic...
Mar 11, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis to supply Hadlima to US government
South Korea’s Samsung Bioepis and the US-based Organon, the local partner company of Samsung group's biopharmaceutical research and developmen...
Feb 21, 2024 (Gmt+09:00)
-
Bio & Pharma
Aprogen gets OK Phase 3 trials in India for Herceptin biosimilar
South Korea’s biopharmaceutical company Aprogen Inc. announced on Monday that its Phase 3 clinical trial for a biosimilar of Herceptin (trastu...
Feb 05, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to export three anticancer drugs to Europe
South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...
Jan 18, 2024 (Gmt+09:00)
-
Steel
Korean steelmakers mull anti-dumping suit vs Chinese, Japanese firms
Under growing pressure from increased imports of cheap Chinese and Japanese steel products, South Korean steelmakers are considering filing an anti-...
Jan 17, 2024 (Gmt+09:00)
-
Bio & Pharma
LG Chem to start phase 3 for head, neck cancer drug in US
South Korea’s LG Chem Ltd. announced on Wednesday that its US-based subsidiary Aveo Pharmaceuticals will start Phase 3 clinical trials for its...
Jan 17, 2024 (Gmt+09:00)
-
Bio & Pharma
Roche to use Biodyne’s tech for cervical cancer diagnostic kits
Roche, a Swiss multinational healthcare company, is set to use a South Korean company’s technology for cervical cancer diagnostic kits.Biodyne...
Jan 16, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion Holdings eyes Nasdaq IPO by early 2025: chairman
South Korean biosimilar giant Celltrion Group is planning to debut on the Nasdaq market by early 2025, founder and Chairman Seo Jung-jin said at the...
Jan 16, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to expand Yuflyma supply network in Europe
South Korea’s Celltrion Inc. announced on Friday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatment ...
Jan 12, 2024 (Gmt+09:00)
-
Bio & Pharma
SK Biopharm, Dong-A ST sign licensing deal of Cenobamate
South Korea's SK Biopharmaceuticals Co. announced on Thursday that it has signed a contract with Dong-A ST to transfer the rights to commercialize t...
Jan 04, 2024 (Gmt+09:00)
-
Bio & Pharma
MedPacto gets FDA OK for colorectal cancer drug clinical trial
South Korea's biotech company MedPacto Inc. announced on Tuesday that it has got approval from the US Food and Drug Administration (FDA) for its I...
Jan 03, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
Celltrion to sell portfolio of Takeda drugs to CBC Group
South Korea’s Celltrion Inc. will divest of a portfolio of Takeda Pharmaceutical's prescription medicines sold in Asia to CBC Group, a Singapo...
Jan 01, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval of Xolair biosimilar in Canada
South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has applied for CT-P39, a biosimilar of the treatment of asth...
Dec 27, 2023 (Gmt+09:00)
-
Bio & Pharma
NGeneBio gets approval for cancer diagnostic device in Thailand
South Korean medical diagnostic company NGeneBio Co. announced on Friday that it has received approval for the sale of its in-vitro diagnostic medic...
Dec 22, 2023 (Gmt+09:00)
-
Aerospace & Defense
Hanwha wins S.Korean military anti-drone system deals
South Korean aerospace and defense maker Hanwha Systems Co. is set to establish a military system to cope with small unmanned aerial vehicles (UAVs)...
Dec 22, 2023 (Gmt+09:00)
-
Bio & Pharma
Lunit acquires NZ-based AI diagnostics firm Volpara
South Korean medical AI company Lunit announced on Thursday that it will acquire New Zealand-based AI breast cancer diagnostics solutions company Vo...
Dec 14, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea’s GC Cell targets global cell therapy CDMO business
GC Cell Corp., an affiliate of South Korea’s major pharmaceutical company GC Biopharma Corp., is targeting the cell therapy contract developme...
Dec 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Vegzelma listed on US PBM preferred drug list
South Korea's Celltrion Healthcare Co. announced on Tuesday that its anti-cancer biosimilar Vegzelma (active ingredient: bevacizumab) was listed as ...
Dec 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare's Herzuma selected as funded brand in NZ
Celltrion Healthcare Co. announced on Thursday that its biosimilar anticancer drug Herzuma (active ingredient trastuzumab) for breast and gastr...
Dec 07, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval in Europe for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...
Nov 24, 2023 (Gmt+09:00)
-
Shipping & Shipbuilding
HD Hyundai builds Aegis destroyer with anti-ballistic missiles
ULSAN, South Korea – At the shipyard of HD Hyundai Heavy Industries Co. on Nov. 20 in Ulsan, South Gyeongsang Province, South Korea's ne...
Nov 22, 2023 (Gmt+09:00)
-
Bio & Pharma
Cytogen, Japan NCCH collaborate on cancer research
South Korea's Cytogen, Inc. announced on Monday it will start cancer research using circulating tumor cells (CTC) with the National Cancer Center Ho...
Nov 20, 2023 (Gmt+09:00)
-
Bio & Pharma
South Korean bio, pharma industry set to take leap
South Korea’s chemical maker LG Chem Ltd. is expected to reap more than 1 trillion won ($768.5 million) in sales this year from its new growth...
Nov 15, 2023 (Gmt+09:00)
-
Artificial intelligence
Lunit gets FDA approval for AI cancer diagnosis solution
South Korean medical AI company Lunit said on Tuesday its Lunit Insight DBT, an AI imaging diagnosis solution aiding in breast cancer diagnosis, has...
Nov 14, 2023 (Gmt+09:00)
-
Bio & Pharma
'World-class bispecific antibody technology of ABL Bio'
MADRID - "The clinical Phase 1 results of the immune-oncology candidate ABL111, developed in collaboration with ABL Bio, have been selected as the b...
Nov 13, 2023 (Gmt+09:00)